<DOC>
	<DOCNO>NCT02827370</DOCNO>
	<brief_summary>The purpose study determine target dietary change enhance effect neo-adjuvant chemotherapy</brief_summary>
	<brief_title>CAREFOR : Precision Medicine Driving Precision Nutrition Treatment NeoAdjuvant Breast Cancer</brief_title>
	<detailed_description>Primary objective : I To determine dietary alternation design downregulate dominate molecular driver individual ' breast cancer enhance effect neoadjuvant chemotherapy allow increase pathologic complete response rate . Secondary objective I ) Investigator measurable change molecular patient characteristic precision nutrition determine metric evaluation treatment future study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Pathologically proven invasive breast cancer Planned neoadjuvant chemotherapy determine judgment medical oncologist The patient must female Age ≥ 18 Nonmetastatic noninflammatory breast cancer History/physical examination , include breast exam documentation weight Karnofsky Performance Status 80100 % least 60 day prior study entry . Women childbearing potential must nonpregnant nonlactating willing use medically acceptable form contraception chemotherapy Patient must capable provide study specific informed consent prior study entry BMI ≥21 Weight ≥120lbs No prior history nonbreast malignancy past 1 year unless non melanomatous skin lesion carcinoma situ cervix . Patient must Acquired Immune Deficiency Syndrome ( AIDS ) HIV positive base upon current CDC definition ; note , however , HIV test require entry protocol . The need exclude patient AIDS HIV protocol necessary antiretrovirals may alter patient metabolism . Patient may active Gastrointestinal/Malabsorption disorder discretion Principal Investigator may include : Chronic Pancreatitis Chronic Diarrhea Vomiting Active Eating Disorder No history current active drug/alcohol dependence . No patient decisional impairment . Patient male . Age &lt; 18 year Clinical stage IV cancer Inflammatory breast cancer ( T4d ) Women childbearing potential positive serum beta hCG . Decision impair patient . BMI &lt; 21 Weight &lt; 120lbs Weight loss ≥10 % last 3 mos Prior invasive nonbreast malignancy ( except nonmelanomatous skin cancer , carcinoma situ cervix ) unless disease free minimum 1 year prior registration Nonepithelial breast malignancy sarcoma lymphoma Active Gastrointestinal/Malabsorption disorder discretion Principal Investigator may include : Chronic Diarrhea Vomiting Active Eating Disorder Active drug/alcohol dependence abuse history .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>